About Brensocatib API
Therapeutic CategoryPulmonology
CAS Number
1802148‑05‑5
API Technology
Small‑molecule synthetic API
Dose Form
片剂
Dr Reddy's Development Status
开发中
Mechanism of action
Brensocatib inhibits dipeptidyl peptidase‑1 (DPP1), an enzyme responsible for activating neutrophil serine proteases (NSPs).
By inhibiting DPP1, it prevents activation of neutrophil elastase, proteinase‑3, and cathepsin‑G in neutrophil precursors.
This leads to:
Reduced neutrophil‑driven airway inflammation
Decreased lung tissue damage
Lower frequency of pulmonary exacerbations
Acts upstream of inflammation, unlike symptomatic anti‑inflammatory therapies.
Indication
Treatment of non‑cystic fibrosis bronchiectasis (NCFB) in:
Adult and pediatric patients ≥12 years of age
Related APIs
Brensocatib
Pulmonology
Request for Quotation
Get in touch with us by filling out the form below. Our team will reach out to you shortly!
免责声明
本網站上的任何信息，包括對任何產品或服務的任何提及，均不構成銷售要約或被解釋為代表銷售要約。受有效專利保護的產品不得提供或供應用於商業用途。但是，在某些情況下，雷迪博士可自行決定並根據當地法律要求，在存在此類監管豁免的任何地方，提供此類產品的研究數量，以根據《印度專利法》第 107A 條（Bolar 豁免）進行監管提交。購買者應對其各自市場的產品或服務（包括專利情況）進行獨立評估，並對所有與專利相關的責任負責。 Dr. Reddy's 不承擔任何明示或暗示的保證，包括但不限於適銷性、適用於特定用途和非侵權的保證。